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ABSTRACT
Promising new hallmarks of cancer is alteration of energy metabolism that 
involves molecular mechanisms shifting cancer cells to aerobe glycolysis. Our goal 
was to evaluate the correlation between mutation in the commonly mutated tumor 
suppressor gene TP53 and metabolism. We established a database comprising 
mutation and RNA-seq expression data of the TCGA repository and performed receiver 
operating characteristics (ROC) analysis to compare expression of each gene between 
TP53 mutated and wild type samples. All together 762 breast cancer samples were 
evaluated of which 215 had TP53 mutation. Top up-regulated metabolic genes 
include glycolytic enzymes (e.g. HK3, GPI, GAPDH, PGK1, ENO1), glycolysis regulator 
(PDK1) and pentose phosphate pathway enzymes (PGD, TKT, RPIA). Gluconeogenesis 
enzymes (G6PC3, FBP1) were down-regulated. Oxygen consumption and extracellular 
acidification rates were measured in TP53 wild type and mutant breast cell lines 
with a microfluorimetric analyzer. Applying metabolic inhibitors in the presence 
and absence of D-glucose and L-glutamine in cell culture experiments resulted in 
higher glycolytic and mitochondrial activity in TP53 mutant breast cancer cell lines. 
In summary, TP53 mutation influences energy metabolism at multiple levels. Our 
results provide evidence for the synergistic activation of multiple hallmarks linking 
to these the mutation status of a key driver gene.
INTRODUCTION
Chronic cell proliferation requires corresponding 
adjustment of energy metabolism in order to fuel rapid 
cell growth and division. Normal cells process glucose 
to pyruvate via glycolysis, and thereafter to CO2 in the 
mitochondria via an affiliated ATP producer mechanism, 
the oxidative phosphorylation. A feature of cancer cell 
metabolism first observed by Otto Warburg in 1956 
involves their capability to reprogram glucose metabolism 
(increase glycolysis rate) in aerobic conditions [1]. By 
limiting their energy metabolism this leads to a state that 
has been termed “aerobic glycolysis” (also known as the 
“Warburg effect”). Increased rate of glycolysis allows 
the diversion of glycolytic intermediates into various 
biosynthetic pathways that are required for assembling 
new cells [2]. The very same process can also be observed 
in normal, rapidly dividing embryonic cells [3]. In 
addition, high glycolysis in tumor cells correlates with the 
degree of tumor malignancy, its ability to form metastasis 
and has been showed to be related to resistance against 
chemo- and radiotherapy treatments [4, 5].
Driver genes behind this process include GLUT1, 
which enables the uptake of glucose necessary for the 
process and the HIF1 alpha and HIF2 alpha transcription 
factors responsible for the initiation of glycolysis by 
triggering the expression of multiple target genes [6]. 
Altered energy metabolism is in close connection to the six 
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established hallmarks of cancer (activation of oncogenes, 
loss of tumor suppressors, replicative immortality, 
evasion of apoptosis, induction of neoangiogenesis and of 
metastases). Moreover, transformed energy metabolism is 
proving to be so widespread in cancer cells that it has been 
recently accepted as a new hallmark of cancer [7].
TP53 is frequently mutated in human cancers; 
somatic TP53 mutations occur in almost every type of 
human tumors and in over 50% of all tumors [8]. As 
the “guardian of the genome”, TP53 plays a key role in 
maintaining genomic stability and tumor prevention [9]. 
In breast cancer, genes correlated to TP53 mutation predict 
the risk of tumor relapse [10]. TP53 positively correlates 
to MKI67 expression and thus to tumor proliferation [11]. 
In other tumors with low TP53 mutation rates, TP53 is 
often inactivated by alternative mechanisms [12]. TP53 
can also impact glycolysis through mechanisms including 
transcriptionally repressing the expression of glucose 
transporters, down-regulating rate limiting enzymes of 
glycolysis, decreasing the expression of transporters 
responsible for lactate extrusion and negatively regulating 
the AKT/mTOR and NF-κB signaling pathways [13]. 
TP53 can also modulate expression of glycolytic enzymes 
like phosphoglycerate mutase [14] and TIGAR, a 
stimulator of gluconeogenesis and the pentose phosphate 
pathway [15]. Furthermore it was found that TP53 has 
effect on the ATP level by influencing the mitochondrial 
energy production via disruption of the SCO2 gene [16].
In our research our conceptual idea was that we 
assume that the mutations in TP53 will not only influence 
genes because its tumor suppressor properties but will 
also directly impact enzymes of glycolysis and citrate 
cycle involved in the energy metabolism of the cells. This 
property would enable to simultaneously influence multiple 
key hallmarks of cancer by a single genetic mutation. To 
validate this hypothesis, we utilized a large breast cancer 
cohort where both mutation state and gene expression 
levels were available simultaneously for each gene. To 
evaluate the expression of genes involved in metabolic 
cycles we designated sub-cohorts based on TP53 mutation 
state (using coding and silent mutations as well). Using 
these datasets we demonstrate that genes driven by TP53 
mutation status have a high relevance in establishing the 
Warburg effect. In our in vitro experiments we analyzed 
metabolic profiles in three breast cancer cell lines with 
different TP53 status (wild type MCF7 and mutated TP53 
in MDA-MB-231 and JIMT-1) and demonstrate that 
glycolytic activity is concomitant with TP53 status.
RESULTS
Assessment of energy metabolism in wild type 
and mutated clinical samples
ROC analysis was performed to identify genes 
associated with TP53 mutation. We identified 2,178 genes 
positively expressed and 1,584 genes negatively regulated 
genes in the mutant TP53 cohort compared to the wild 
type TP53 cohort at p<0.05. When evaluating the type of 
mutation, out of 215 patients with a mutation in TP53, 
210 samples had a coding mutation and only 5 samples 
had a non-coding mutation. Therefore, when running the 
analysis using the coding mutations and all mutations, the 
results were almost identical. We did not performed the 
analysis using the silent mutations only due to the very 
low sample number.
The entire gene list was analyzed based on carbon 
metabolism pathways form the Kyoto Encyclopedia of 
Genes and Genomes (KEGG database) [17]. The up-
regulated gene group had connection with two pathways: 
glucose degradation (glycolysis) and pentose phosphate 
pathway, plus contained a glycolysis regulator. The 
down-regulated genes were connected to two pathways, 
gluconeogenesis and fatty acid oxidation pathway (FAOP), 
and a mitochondrial regulator gene was also included.
Expression changes of the most important genes
ROC results for the 16 top ranking genes that 
had connection to cellular energy metabolisms are 
listed in Table 1. The glycolysis pathway included 
eight up-regulated enzymes, two glucose transporters 
and six carbohydrate modulator enzymes. The glucose 
transporters GLUT5 and GLUT6 mRNA expression were 
almost twofold higher in the mutTP53 breast cancer 
patients than in wtTP53 patients (Figure 1A). Hexokinases 
(HK) perform the first step in most glucose metabolism 
pathways. mRNA expression of one izozyme of HK 
(HK3) was twofold higher in the mutTP53 patient group 
(Figure 1A). Phosphofructokinase (PFKP) enzymes 
process the third step of glycolysis, and its isoform gene 
expression was twofold higher in the mutTP53 group 
(Figure 1B). Glucose-6-phosphate isomerase (GPI) 
gene product performs the second step of glycolysis, 
and its expression was one and a half times as much in 
the mutTP53 patient group than in the wtTP53 patient 
group. The protein product of GAPDH gene converts 
D-glyceraldehyde 3-phosphate into 3-phospho-D-
glyceroyl phosphate via the fifth step of glycolysis, and 
its expression was one and a half times higher in the 
mutTP53 group. The phosphoglycerate kinase 1 (PGK1) 
converts 1,3-diphosphoglycerate to 3-phosphoglycerate 
and phosphorylates ADP to ATP (substrate level 
phosphorylation) during the sixth step, its expression was 
almost one and a half times higher. Enolase 1 (ENO1) 
catalyze the ninth step of glycolysis, its expression was 
one and a half higher in the mutTP53 group (Figure 1C). 
Pyruvate dehydrogenase kinase (PDK1) phosphorylates 
and inactivates pyruvate dehydrogenase complex (PDHc) 
thus decreases glycolytic flux to tricarboxylic acid 
cycle [18], its expression was more than one and a half 
times higher in the mutTP53 group. Pentose phosphate 
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pathway (PPP) is a glycolysis parallel metabolic pathway 
that generates materials for the reductive biosynthesis 
reactions. Three up-regulated genes participate in PPP 
including 6-phosphogluconate dehydrogenase (PGD), 
ribose 5-phosphate isomerase (RPIA), and transketolase 
(TKT) – each of these genes was up-regulated (Figure 1E).
Genes enclosed in the down-regulated groups 
included two out of three key enzymes of gluconeogenesis, 
glucose-6-phosphatase (G6P) and fructose-1,6-
bisphosphatase (FBP1). Gluconeogenesis is a parallel 
pathway compared to glycolysis, its enzymes perform the 
reversible conversion of carbohydrate substrates to glucose 
[18]. The G6PC3 gene encodes the catalytic subunit of 
G6P. RNA expression of both of the two gluconeogenesis 
enzymes was almost half as much in the mutTP53 group 
as in the wtTP53 patient group (Figure 1F). The analysis 
showed other down-regulated genes, such as the GLS2 and 
GAMT (Figure 1D). GLS2 gene encodes a mitochondrial 
glutaminase that is an enzyme in glutaminolysis, and 
promotes mitochondrial respiration and increases ATP 
generation [19]. RNA expression of GLS2 was less than 
half in the mutTP53 group than in the wtTP53 patient 
Table 1: Energy metabolism genes with the highest AUC value identified in mutant TP53 breast cancer patients 
GENE CODED PROTEIN AUC P-VALUE
GLYCOLYSIS ENZYMES
SLC2A5 Solute carrier family 2, 
member 5 (GLUT5) 0.70 1.9e-17
SLC2A6 Solute carrier family 2, 
member6 (GLUT6) 0.73 4.1e-21
HK3 Hexokinase 3 0.73 6.8e-21
GPI Glucose-6-phosphate isomerase 0.70 2.6e-16
PFKP Phosphofructokinase P 0.70 1.6e-17
GAPDH Glyceraldehyde-3-phosphate dehydrogenase 0.68 5.7e-14
PGK1 Phosphoglycerate kinase 1 0.72 1.1e-19
ENO1 Enolase 1 0.77 1.1e-27
GLUCONEOGENESIS ENZYMES
G6PC3 Glucose-6-phosphatase catalytic 3 -0.70 -5.4e-17
FBP1 Fructose-1,6-biphosphatase 1 -0.70 -4.2e-17
REGULATORS OF ENERGY METABOLISMS
GLYCOLYSIS REGULATORS
PDK1 Pyruvate dehydrogenase 
kinase 1
0.70 4.3e-17
MITOCHONDRIAL REGULATORS
GLS2 Mitochondrial glutaminase 2 -0.73 -7.0e-22
FATTY ACID OXIDATION PATHWAY REGULATORS
GAMT Guanidinoacetate N-methyltransferase -0.71 -8.7e-19
PENTOSE PHOSPHATE PATHWAY ENZYMES
PGD 6-phosphogluconate dehydrogenase 0.67 4.4e-13
RPIA Ribose 5-phosphate 
isomerase A
0.69 2.9e-15
TKT Transketolase 0.69 8.1e-16
Positive AUC values correspond to up regulation and negative AUC values to down regulation.
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group. The GAMT gene encoded guanidinoacetate 
N-methyltransferase that is part of the creatine synthesis, 
and may have a TP53-dependent regulator function of 
fatty acid oxidation [20].
In summary, mutant TP53 influenced genes in 
the glycolysis and other energy metabolic pathways at 
multiple levels. The expression changes for each of the 
involved genes are summarized in Figure 2.
Cell culture setup
To investigate the effect of TP53 mutation, we 
compared the metabolic activity between wtTP53 and 
mutTP53 breast tumor cell lines. First, TP53 mutations 
were validated by sequencing the appropriate exon. 
Location of the mutations were from the Catalogue of 
somatic mutations in cancer (COSMIC) database. In case 
of JIMT-1 the amino acid exchange from arginine (R, 
CGG) to tryptophan (W, TGG) is located in the seventh 
exon at amino acid #248 (Supplementary Figure 1B). In 
case of MDA-MB-231 the amino acid exchange from 
arginine (R, AGA) to lysine (K, AAA) is located in the 
eighth exon at amino acid #280. The TP53 mutation 
in MDA-MB-231 cell line can explain the previously 
described resistance of the cell line against antimetabolites 
[21]. We have determined all 11 exons in MCF7 to validate 
the wild type sequence (data not shown).
Gene expression in the cell lines
The expression difference for a selected set of ten 
genes were further validated by RT-PCR in the cell lines. 
Figure 1: Gene expression of glycolysis enzymes in mutant TP53 cohort (mutTP53, n=215) and in wild type TP53 cohort 
(wtTP53, n=547) breast cancer samples. White columns show the mutTP53 patient group gene expression level and grey columns 
show the wtTP53 patient group. Data are presented as mean ± 95% confidence interval. A. SLC2A5: Solute carrier family 2 (GLUT5); 
SLC2A6: Solute carrier family 2 (GLUT6); HK3: Hexokinase 3, B. PFKP: Phosphofructokinase P, C. GPI: Glucose-6-phosphate isomerase; 
GAPDH: Glyceraldehyde-3-phosphate dehydrogenase; PGK1: Phosphoglycerate kinase 1; ENO1: Enolase 1, D. GAMT: guanidinoacetate 
N-methyltransferase, E. PGD: 6-phosphogluconate dehydrogenase; RPIA: Ribose 5-phosphate isomerase; TKT: Transketolase, F. G6PC3: 
Glucose-6-phosphatase catalytic 3, FBP1: Fructose-1,6-biphosphatase 1.
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For nine out of ten genes (ENO1, FBP1, HK3, G6PC3, 
GAPDH, GLS2, PGD, PGK1, and TKT) the expression 
change was parallel in the clinical samples and in the cell 
lines (Supplemental Figure 2.).
Oxygen consumption in DMEM based medium
There were significant differences in absolute 
oxygen consumption among the investigated cell lines. In 
terms of oxygen consumption, MCF-7 cells exhibited the 
highest basal rate followed by MDA-MB-231 and JIMT-1 
cells, in decreasing order. All the cell lines responded to 
oligomycin with a decrease of oxygen consumption rate 
(OCR) showing that oxidative phosphorylation had been 
active in all the cases (Figure 3A). If data were expressed 
as percentages of the basal oxygen consumption rate, 
then, in the presence of oligomycin, even in JIMT-1 cells, 
there was a 70% decrease of the oxidation rate (data not 
shown). Reserve respiratory capacity followed the same 
pattern as the baseline respiration; far the highest value 
was found for MCF-7 and the lowest for JIMT-1 (Figure 
3A). Mitochondrial respiration was found responsible for 
at least 80% of the total oxygen consumption.
Administration of glucose to these cancer cell lines 
resulted in significant decrease in oxygen consumption in 
each case; the most pronounced effect was exhibited by 
JIMT-1 cells (32.9±3.9 %) (Figure 3B). Addition of an 
uncoupler significantly augmented the rate of oxidation in 
both MDA-MB-231 and MCF-7 cells (without glucose) 
(Figure 3A). However, in JIMT-1 cells uncoupler 
Figure 2: Summary of genes involved in the glycolytic processes affected by TP53 mutation. Blue boxes indicate genes 
up regulated in TP53 mutant samples, green boxes indicate down regulated genes. Blue arrows mark the glycolysis pathway, red arrows 
indicate the gluconeogenesis pathway and purple arrows indicate regulators of related metabolism pathways.
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dinitrophenol (DNP) stimulated respiration showed a 
higher rate relative to the one in the presence of glucose, 
although it was still beneath the baseline (Figure 3B).
Extracellular acidification in DMEM based 
medium
The basal rates of pH change showed remarkable 
parallelisms to basal rates of oxygen consumptions. The 
highest rate of acidification was measured in MCF-7 
cells whereas the lowest rate was found in JIMT-1 cells 
(Figure 3C). In DMEM based medium the energy donor 
substrates are mainly those amino acids that are capable 
of being decomposed to TCA cycle intermediates. 
Consequently, acidification in this medium can principally 
be attributed to the CO2 that is released during (oxidative) 
decarboxylation. Under these conditions oligomycin slows 
acidification down as it hampers mitochondrial oxidation 
involving the TCA cycle and reactions of oxidative 
decarboxylation.
When DNP alleviated the oligomycin mediated 
inhibition, TCA cycle could start working with maximal 
speed and pH changes could turn to be of the highest rates. 
Inhibition of mitochondrial metabolism drove the rate of 
acidification well below the baseline (Figure 3C). Glucose 
significantly enhanced the extracellular acidification rate 
(ECAR) in the DMEM based medium for all the cell lines 
(Figure 3D). The most pronounced elevation was observed 
in JIMT-1 cells where the rate of acidification was 
increased by a factor of twelve; in MCF-7 cells glucose 
Figure 3: Higher glycolytic and mitochondrial activity observed in TP53 mutant cell lines. Oxygen consumption (OCR) and 
extracellular acidification rates (ECAR) of JIMT-1, MCF-7 and MDA-MB-231 breast cancer cells (legends are displayed in panels F and I) 
measured in DMEM-based media A-D. or Extracellular assay media.
(Continued )
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stimulated acidification resulted only in a less than twofold 
increase. In the presence of glucose, MDA-MB-231 and 
MCF-7 cells responded to oligomycin with a significant 
further acidification, while in JIMT-1 cells the effect of 
oligomycin was not significant (Figure 3D).
Oxygen consumption in extracellular assay 
medium
Cells were kept in energy substrate-free (EC) 
medium for 2.5 hours before measurement. Interestingly 
this starvation period did not affect significantly the basal 
rate of respiration indicating that cells could fulfill their 
energy requirements by mobilizing their own energy 
stores; probably autophagic mechanisms have also been 
activated. The basal rate of O2 consumption was thus the 
highest in MCF-7 cells, followed by MDA-MB-231 and 
JIMT-1 cells (Figure 3E) (similarly to that of experiments 
performed in DMEM-based media). All of the cell lines 
responded well to oligomycin; the magnitude of the 
decline of respiration was found to be approximately 60% 
indicating that mitochondria were well coupled (Figure 
Figure 3 (Continued): E-H. OCR and ECAR were determined using a microfluorimetric Seahorse XF96 Analyzer. Cells were measured 
i) in the absence (A,C) or presence (B,D) of D-glucose in DMEM-based media and ii) in the presence of D-glucose (E,G). or L-glutamine 
(F,H). as single substrates in Extracellular assay media. Bioenergetic and glycolytic functions were assessed upon addition of various 
metabolic inhibitors (e.g. oligomycin (“oligo”), an inhibitor of the mitochondrial FoF1 ATP-synthase or antimycin A + rotenone (“A+R”), 
inhibitors of the mitochondrial respiratory chain). The highest OCR was exhibited with the uncoupler 2,4-dinitrophenol (DNP) given. 
D-glucose (10 mM), L-glutamine (2.5 mM), oligomycin (2 μM), 2,4-dinitrophenol (100 μM), antimycin A + rotenone (1-1 μM; all in final 
concentrations) were given as displayed on plots. Results are averages of measurements performed on three consecutive preparations of 
each individual cell culture (N=12-24, ~20,000 cells/well); individual data points are represented as mean ± S.E.M. The blue dashed lines 
in B and D serve as an interpretation guideline – they represent a schematic average value of multiple time point measurements and the 
double arrow indicate the key oxygen consumption (B) and extracellular acidification (D).
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3E). Uncoupler mediated stimulation of respiration was of 
the smallest magnitude in JIMT-1 cells, even when oxygen 
consumption was normalized to the baseline.
Glucose triggered a significant drop in O2 
consumption in all of the cell lines; the greatest effect 
was observed in JIMT-1 cells (48.5±5.5 %) (Figure 3E). 
All of the cell lines responded to oligomycin in a similar 
fashion. The rate of reserve respiration measured in the 
presence of an uncoupler was the smallest in JIMT-1 cells; 
in the presence of glucose it has not even reached the basal 
respiratory rate.
Glutamine induced a small (<20%), but significant 
increase in O2 consumption in JIMT-1 and MDA-MB-231 
cells (Figure 3F). The uncoupler DNP enhanced the rate 
of respiration to higher than the baseline in all of the 
cell lines. Although, JIMT-1 cells exhibited the smallest 
elevation of the rate, but even their oxygen consumption 
was now more intense than the one represented by the 
baseline indicating that glutamine was indeed a good 
respiratory substrate in the absence of glucose for this 
mainly glycolytic cell line (Figure 3F).
Extracellular acidification in extracellular assay 
medium
In EC medium the smallest rate of acidification 
was measured for JIMT-1 cells. There was no significant 
difference between the acidification rates of MDA-
MB-231 and MCF-7 cells. However, glucose augmented 
the acidification rate of JIMT-1 cells 15-fold (Figure 
3G) indicating their extreme dependence on glycolysis. 
Similarly to data collected in DMEM based medium, to a 
lesser extent glycolysis also accelerated in MDA-MB-231 
and MCF-7 cell lines upon addition of glucose and this 
acidification was further stimulated by oligomycin. The 
maximal acidification capacity was similar in the three 
cell lines investigated. Glutamine enhanced the rate of 
oxidation, but this elevation was not accompanied by an 
elevation of the rate of acidification (Figure 3H). This 
lack of acidification can potentially be explained by the 
release of ammonia due to glutaminase and glutamate 
dehydrogenase reactions.
DISCUSSION
Cancer cell lines show many characteristic tumor-
specific alterations in glycolysis. Cancer cells may 
consume more than 10 times more glucose than their 
normal counterparts [22]. High rate of glucose uptake can 
be detected and used as a diagnosis of cancer. Accelerated 
glucose metabolism in cancer is associated with increased 
expression of glucose transporters, especially GLUT1. 
TP53 can repress at the transcriptional level GLUT1-
4 gene expression that results in decreased glucose 
uptake [23]. In our study, multiple genes in metabolic 
pathways were significantly linked to TP53 mutation 
including Hexokinase 3, Phosphofructokinase, Platelet 
(PFKP) and Pyruvate dehydrogenase kinase. Under stress 
condition, TP53 can gear up glucose uptake by increasing 
hexokinase transcription [24]. Glucose molecules have 
to be phosphorylated intracellularly by hexokinases 
(HK). HK II is upregulated in many cancer cell types 
[25]. Phosphofructokinase 1 (PFK1) is the rate limiting 
step of glycolysis. In tumor cells a post-translationally 
modified form is expressed frequently [26]. One the major 
mechanisms responsible for the Warburg phenomenon is 
that HIF-1α and TP53 have effect on the regulation of 
pyruvate dehydrogenase complex [27].
TP53 can promote fatty acid oxidation when 
available glucose levels are low to generate ATP in the 
tricarboxylic acid (TCA) cycle using alternative energy 
sources. The TP53-dependent regulation of fatty acid 
oxidation pathway occurs by activation of GAMT [28]. 
Gluconeogenesis, a reverse glycolytic pathway, generates 
glucose from small noncarbohydrate precursors. Zhang 
et al. [29] showed roles for TP53 in the down-regulation 
of gluconeogenesis both in vitro in colon and liver 
cancer cells and in vivo, by down regulation the gene 
expression of PCK and G6PC, the rate limiting enzymes 
of gluconeogenesis. Our analysis showed that the gene 
expression alterations between mutant and wild type TP53 
patients showed higher expression of glucose transporters 
that contributes to the higher uptake of glucose, and 
higher expression of key glycolysis enzymes and pentose 
phosphate pathway (PPP) enzymes.
We performed the analysis for patients with all 
mutations and patients with a coding mutation only 
separately. Almost all patients had a coding mutation 
in TP53 – only five patient had a silent alteration. This 
resulted in almost identical effect of a TP53 alteration 
in all and in coding patients only. The extremely low 
prevalence of non-coding mutations further emphasize the 
importance of TP53.
Song and colleagues [30] published a proteomic 
comparison between normal and breast cancer tissues. 
Differentially expressed proteins in tumor tissues were 
related to glycolysis/gluconeogenesis among other 
pathways. Overexpressed proteins included GAPDH, 
ENO1, lactate dehydrogenase (LDH), pyruvate kinase 
(PKM2) and aldolase A (ALDOA). The fact that these 
proteins were up-regulated in the invasive carcinoma 
group supports the general concept that rapid growing 
tumor cells show higher rate of glucose metabolism 
than normal cells [30]. At the same time mutant TP53 
negatively affected the expression of gluconeogenesis, 
the glucose synthetic pathway, and the fatty acid 
oxidation pathway that contributes to the degradation 
of fatty acids. Recent studies suggest that some of the 
glucose metabolism enzymes – including GPI and PGK, 
genes identified in our analysis – are multi-functional 
proteins. The encoded protein of GPI is also referred to as 
autocrine motility factor based on an additional function 
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as a tumor-secreted cytokine and angiogenic factor [31]. 
The glycolysis enzyme PGK participates in angiogenesis 
by functioning to reduce disulfide bonds in the serine 
protease, plasmin by tumor cells [32].
Li and colleagues [33] exposed that MDAMB-231 
and another mutTP53 cell line (T47D) consumed 
significantly more glucose and secreted more lactate than 
the non-tumorgenic and wtTP53 cell line, MCF10A. In 
the two mutTP53 cell lines (MDA-MB-231 and T47D) 
80-94% of the glucose consumed was used to make 
lactate, while in the MCF10A only the 50% of glucose 
consumed was used to make lactate. In our study we show 
that wtTP53 MCF-7 cells display the lowest glycolytic 
activity in the presence of glucose in amino acid rich 
media. In DMEM based medium, MCF-7 cells were the 
most oxidative ones among the investigated cells. JIMT-
1 cells exhibited the highest rate of glycolysis and the 
most pronounced inhibition of oxidative metabolism in 
the presence of glucose. MDA-MB-231 cells showed a 
moderate glycolytic activity and mitochondrial activity 
among these cell lines. None of the cell lines investigated 
here presented with a high glutamine dependence of 
oxidation.
During the past years significant efforts have 
been dedicated to the identification of mediators 
that selectively eliminate cancer cells based on their 
metabolic alterations, some of them now close to clinical 
evaluation [34]. Multiple attempts have been executed to 
inhibit the rate limiting enzymes of glycolysis, first the 
unselective inhibitor of hexokinase 2-deoxy-p-glucose (2-
DG) was added to patients with glioma [35]. Promising 
preclinical results showed with other HK inhibitors, 
3-bromopyruvate (3-BP) [36] and methyl jasmonate 
[37] with anticancer effects in mouse models. However, 
clinical development of 2-DP and 3-BP hexokinase 
inhibitors has been discontinued – most probably the 
similarities between malignant cell and normal cell 
(manly highly proliferative cells) metabolisms will make 
it difficult to select the appropriate patient cohort eligible 
for such treatments [38].
Lonidamine, a derivative of indazole-3-carboxylic 
acid delivered impressive results to inhibit aerobic 
glycolysis in cancer cells by inhibit HK in clinical trials 
[39]. Preclinical data showed that inhibition of glucose 
transporters (GLUT1 inhibition with WZB117 or with 
silybin) also have antineoplastic effects [40, 41]. Further 
studies have shown that koningic acid, a potent and 
selective inhibitor of GAPDH, kills a broad range of highly 
glycolytic cell lines [42]. Imatinib treatment decreased the 
activity of both HK and GAPDH in leukemia and myeloid 
tumors [43]. Pyruvate dehydrogenase kinase (PDK) is 
often overexpressed in malignant cells, the dichloroacetate 
(DCA) that originally used in lactic acidosis therapy 
inhibits PDK, and results mitochondrial defects in 
cancer cells used by patients with glioblasoma [44]. 
Oxythiamine is a thiamine antagonist, inhibits both PDK 
and transketolase (TKT), and responsible for significant 
anticancer activity [45].
We have to mention a limitation of present study: 
the investigated cell lines also harbor additional difference 
in addition to mutations in TP53. At the same time, the 
primary analysis of the study is based on evaluating a large 
patient cohorts. The identified genes as well as the study 
messages holds therefore even without the cell culture 
experiments. Future studies with additional cell lines will 
be needed to further validate the effect of each gene on the 
metabolic profile in TP53 mutant and wild type cell lines.
In summary, here we show in a large patient cohort 
that TP53 mutation status simultaneously affects multiple 
metabolic pathways. The utilization of metabolic inhibitors 
in cell culture experiments lead to higher glycolytic and 
mitochondrial activity in TP53 mutant breast cancer cell 
lines.
MATERIALS AND METHODS
In silico analyses
Database setup
Breast cancer samples from the TCGA database 
with genome-wide sequencing, gene expression and 
clinical data for 762 patients were used in the statistical 
analysis. We analyzed n=547 TP53 wild type and n=215 
TP53 mutant BC patient samples. Clinical characteristics 
for all these patients are summarized in Supplementary 
Table 1.
NGS data download
Genome-wide sequencing data and RNA-seq data 
for breast cancer patients were obtained from The Cancer 
Genome Atlas (TCGA) of the National Cancer Institute 
(http://cancergenome.nih.gov/) [46]. The aligned TCGA 
datasets were downloaded from the CGHub repository 
(website: https://cghub.ucsc.edu/) using the CGHub 
download client software GeneTorrent (version 3.8.5).
Mutation calling
Mutation calling and annotation was done with 
MuTect using default parameters. The human reference 
genomes GRCh37, GRCh37-lite and HG19used for 
mutation calling were downloaded according to the 
CGHub website’s “Reference Assemblies” guideline 
(available at https://gdc.cancer.gov/download-gdc-
reference-files). To reduce the total number of mutations, 
we only accepted somatic mutations that were labeled 
with 'KEEP' according to the MutTect judgment algorithm, 
and were present in at least four reads with a minimum 
of 20 fold read coverage. The identified mutations were 
annotated with MuTect using the most recent versions 
of the dbSNP (build 139) and COSMIC (version 68) 
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databases. The identified sequence variations were 
functionally annotated using SNPeff v3.5 [47]. The 
reference databases used with SNPEff were downloaded 
with the SNPeff downloader. Mutations were defined as 
coding mutations in case they changed the amino acid 
sequence. Coding mutations categories include missense, 
start/stop loss, start/stop gain, and splice site mutations. 
Non coding mutations were mutations that do not fall in 
any of the coding mutation categories.
Processing of RNA-seq data
RNA-seq data for breast cancer patients was 
obtained from the TCGA repository for those patients 
who also had mutation data as well. We downloaded pre-
processed level 3 data generated using the Illumina HiSeq 
2000 RNA Sequencing Version 2 platform. Expression 
levels for these samples were determined using a 
combination of MapSplice and RSEM. Individual patient 
files were merged in R using into a single database.
Statistical analysis
Separate ROC analysis was performed for the 
expression of each gene grouped by TP53 mutation 
status. The analysis was performed for all mutations, for 
coding mutations and for silent mutations separately. ROC 
analysis was completed in the R statistical environment 
(http://www.r-project.org) using the ROC Bioconductor 
library (http://www.bioconductor.org) as described 
previously [48]. Statistical significance was set at FDR 
adjusted p value<0.05.
In vitro experiments
Cell lines
Human breast cancer cell lines MCF7, MDA-
MB-231 and JIMT-1 were obtained from the American 
Type Culture Collection (Manassas, VA, USA). Cell 
lines were cultured in RPMI medium supplemented with 
10% fetal bovine serum with 1% penicillin-streptomycin 
and 0,1% amphotericin (Life Technologies) as described 
previously [49]. Cells were grown at 37°C under a 
humidified atmosphere of 95% air and 5% CO2.
STR analysis
Cell line verification was completed by Short 
tandem repeat (STR) analysis on 9 exact loci of the 
human genome. Genomic DNA was extracted by DNeasy 
Kit (Qiagen) according to the protocol provided by 
the manufacturer. DNA concentration and clarity was 
confirmed by Nanodrop ND-1000. The SRT analysis was 
accomplished by Fragment Analysis Facility at Johns 
Hopkins University (Baltimore, USA). Then, results were 
compared to the STR database of the German Collection 
of Microorganisms and Cell Cultures at the Leibniz 
Institute (http://www.dsmz.de). All the tested cell lines 
were contamination free.
RNA isolation
RNA was isolated from 1 × 107 cells in logarithmic 
growth phase using the Qiagen RNeasy Mini Kit 
following the manufacturer's protocol (Qiagen GmbH, 
Hilden, Germany). Isolated total RNA concentrations 
were measured by NanoDrop ND-1000 spectrophotometer 
(BCM, Houston, TX, USA). RNA samples were stored at 
−80°C.
RT-PCR
RT-PCR assay was performed with PikoTM Thermal 
Cycler (Thermo Fisher Scientific Inc.) using a OneStep 
RT–PCR Kit (Qiagen GmbH) as described in the 
manufacturer's instructions. Gene-specific PCR primers 
(IDT&Bio-Science Kft., Hungary) were designed by 
Primer3 software (http://frodo.wi.mit.edu/) and their 
binding site was verified by NCBI BLAST (http://
blast.ncbi.nlm.nih.gov/Blast.cgi). Optimal Tm of each 
primer was set at 59°C. Amplification cycles were 
optimized for each gene according to different gene 
expressions. Then, RT-PCR reaction for wild type and 
mutant TP 53 cell lines was carried out for each gene 
with an identical amplification cycle using 0.5 μg of 
total RNA. Amplification products were separated on a 
2% agarose gel stained with GR Safe Nucleic Acid Gel 
Stain (Excellgen). Results were visualized and recorded 
by using the Glite900 BW Gel Scanner (Pacific Image 
Electronics). The analysis was repeated three times. PCR 
primers, product size and amplification cycles are shown 
in Supplementary Table 2.
TP53 mutation validation
Direct DNA sequencing was performed using 
genomic DNA amplified by polymerase chain reaction. 
In MDA-MB-231 and JIMT-1 mutation detection was 
performed in exons 7-8 of TP53, while in the case of 
MCF7 each of the 11 exons were sequenced in full length 
(Supplementary Figure 1B). Primers were designed to be 
located in intronic sequences to allow amplification of 
genomic DNA only. The used primers and primer features 
are listed in Supplementary Table 3 and illustrated in 
Supplementary Figure 1A.
The PCR reaction was performed in 25 μl final 
volume, containing 500 ng of genomic DNA, 10mM 
of each dNTP (Invitrogen), 10 μM of each of the eight 
primers, 5 units of Taq polymerase (Invitrogen), 2.5 μl 
10x buffer, completing to the final volume with nuclease 
free H2O. The amplification reaction was carried out 
in thermocycler (Swift Maxi, ESCO) with an initial 
denaturation step of 3 min at 94°C, followed by 35 cycles 
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consisting of three steps: 94°C for 30 sec, 53°C for 30 
sec, and 72°C for 2 min. Annealing temperature was 
optimized to the primers melting temperature. The last 
cycle was followed by an extension step of 6 min at 72°C. 
The PCR product was purified, and DNA sequencing 
was performed at the Department of Genomic Medicine 
and Rare Disorders (Semmelweis University, Budapest, 
Hungary). The DNA sequence was analyzed by BioEdit 
and Genedoc programs (Supplementary Figure 1A).
Measurement of cellular respiration and 
glycolytic activity
Mitochondrial and glycolytic functions of the 
wtTP53 MCF-7 and the mutTP53 MDA-MB-231 and 
JIMT-1 cells were monitored using Seahorse XF96 
extracellular flux analyzer. (Seahorse Bioscience, North 
Billerica, MA, USA) Oxygen consumption rate (OCR), as 
a representation of cellular respiration, and extracellular 
acidification rate (ECAR), as a measure of glycolytic 
activity, were assessed in parallel in an assay based on 
microfluorimetric detection using an XF96 Analyzer, 
as previously described [50]. Breast cancer cells were 
plated one day before measurement on Seahorse XF96 
cell culture microplates at a 2x104 cells/well density. 
The growth medium beyond cells was replaced by 
either the DMEM-based or the EC assay medium 2.5 
h before measurement. OCR and ECAR were assessed 
by the XF96 Analyzer based on determination of O2 
concentration and pH.
During the measurement, 20 to 26 μl of substrates 
or inhibitors (at all times prepared freshly in the respective 
assay medium) were administered into each well to reach 
the desired final concentrations. Laboratory chemicals 
were obtained from Sigma (St Louis, MO, USA). 
L-Glutamine was from Merck (Merck KGaA, Darmstadt, 
Germany). All additive stock solutions were each time 
freshly prepared. The composition of the Extracellular 
assay medium (EC) was: 143 mM NaCl, 3 mM KCl, 1 
mM MgCl2, 2 mM CaCl2, 8.3 mM HEPES (pH 7.4). The 
DMEM-based glucose-free medium was purchased from 
Seahorse Bioscience (# 102365, North Billerica, MA, 
USA).
Through OCR and ECAR measurements the 
effects of adding D-glucose/L-glutamine, oligomycin, 
2,4-dinitrophenol (DNP), and antimycin A + rotenone 
were determined. The use of these metabolic modulators 
permits determination of several parameters of 
mitochondrial and glycolytic functions. Key parameters 
of mitochondrial function include basal respiration, 
ATP turnover, proton leak and maximal respiration. 
The difference between the maximal and the basal 
respiration creates a reserve respiratory capacity of 
a cell to create ATP via oxidative phosphorylation in 
response to increased demand of energy (for summary 
see Figure 3B). Key parameters of cellular glycolysis 
include glycolysis, and glycolytic capacity (Figure 3D). 
Glycolytic reserve is the difference between glycolytic 
capacity and glycolysis that reflects to the cellular 
capability to rise the glycolytic rate upon increased 
energy demand.
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